Second US Patient on FSGS Trial

PCRC is proud to be on the front line of trying to eliminate Kidney failure in America. Kamonz Shaw was excited to be the second patient in the US to receive the VX-147, a drug specifically targeting alteration in the APOL1 genotype. If you or someone you know is suffering from FSGS and would like more information on how you might participate in this trial, please contact us at contact@prolatoresearch.com or visit https://www.prolatoresearch.com/fsgs for more information.

Kidney failure is an all too common reality for many people. In the African American population, this is even more pronounced. Even though African Americans only make up 13% of the population, they represent 32% of patients suffering from Kidney failure. It’s believed this is, in part, caused by an alteration in the APOL1 gene that is more common in African American communities.